TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
| Current price | $1.16 | 52-week high | $309.60 |
| Prev. close | $0.81 | 52-week low | $0.42 |
| Day low | $0.81 | Volume | 4,894,700 |
| Day high | $1.20 | Avg. volume | 739,758 |
| 50-day MA | $0.65 | Dividend yield | N/A |
| 200-day MA | $18.80 | Market Cap | 7.09M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Latest RNAZ News From Around the Web
Below are the latest news stories about TRANSCODE THERAPEUTICS INC that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic CancerBOSTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful completion of a preclinical study comprising four independent replicates with its lead therapeutic candidate, TTX-MC138, in pancreatic adenocarcinoma (PDAC). The study demonstrated that TTX-MC138 was effective again |
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer SymposiumBOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year’s San Antonio Breast Cancer Symposium scheduled to take place December 5-9 in San Antonio, TX. The abstract, “Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse |
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesBOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement ag |
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesBOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is act |
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business UpdateBOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress. “In the third quarter of 2023, we successfully completed a follow-on public offering in a very difficult biotech market as we continue our clinical study with our lead therapeutic candidate, an RNA targeted |
RNAZ Price Returns
| 1-mo | 81.25% |
| 3-mo | 93.27% |
| 6-mo | -91.62% |
| 1-year | -99.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -82.40% |
| 2023 | -98.78% |
| 2022 | -73.50% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...